FDA Approves Isatuximab-irfc for Multiple Myeloma
On March 2, 2020, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa®) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Title VIII Support; Trump's 2021 Federal Budget; Ineffective E-Cigarette Ban
When oncology nurses speak, people listen. An op-ed column published February 24, 2020, written by ONS member Janice Phillips, PhD, RN, FAAN, outlined the potential harm to the future of health care and the nursing profession if the Trump administration’s budget cuts are approved. As an oncology nurse, Phillips’ insights have made a difference in Washington before, and she explained that the budget cuts could target key funding for items like nursing development and workforce programs.
- Read more about Title VIII Support; Trump's 2021 Federal Budget; Ineffective E-Cigarette Ban
- Add new comment
Oncology Nursing Specialty Position Defines the Role of the Cancer Nurse
As ONS enters 2020 celebrating both its 45th anniversary and the World Health Organization’s Year of the Nurse, the ONS Board of Directors is positioning the Society for a tremendous year. For its first meeting on January 28, 2020, the Board discussed a number of items critical to its mission and the future of oncology nursing.
- Read more about Oncology Nursing Specialty Position Defines the Role of the Cancer Nurse
- Add new comment
The Case of the Candy-Coated (Mis)Conception
P.G. is a 54-year-old woman who presents to the infusion center to receive her second cycle of chemotherapy for breast cancer. As her oncology nurse, you check the chemotherapy orders and patient history and are concerned to see that her weight has dropped by 10% from baseline, necessitating a change in dosing.
FDA Revamps Anti-Smoking, Vaping Initiative
The growing rates of teen vaping and e-cigarette use have been a focal point at the national legislative level for the past several years. From the U.S. surgeon general’s youth vaping epidemic announcement to the investigation of vaping industry leader Juul, congressional representatives have been busy addressing the issue.
FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer
On February 25, 2020, the U.S. Food and Drug Administration (FDA) approved neratinib (Nerlyn®) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.
AACN Initiative Gives Nurses a Voice Through Voting
During the Year of the Nurse, many organizations are finding ways to promote and champion the expertise and experiences that make up the most trusted profession in the United States. The American Association of Colleges of Nursing (AACN) is focusing on ways nurses will affect the upcoming presidential election, ensuring nursing professionals are registered, educated, and ready to vote in 2020.
Cancer Death Rates See Largest-Ever Single-Year Drop
Overall U.S. cancer mortality fell 2.2% from 2016 to 2017, the largest reduction for a single year, according to the American Cancer Society’s “Cancer Statistics, 2020,” published in CA: A Cancer Journal for Clinicians.
World Gets Closer to Identifying Cancer’s Genomic Drivers
Although most cancers contain four to five driver mutations, those drivers remain unknown for about 5% of cancers, according to results of a series of studies examining genomes from 38 different cancer types. The international Pan-Cancer Analysis of Whole Genomes Consortium reported the findings in a collection of 23 articles published in Nature and other affiliated journals.
Oncology Drug Reference Sheet: Niraparib
Niraparib was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer.